Keros Therapeutics/$KROS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
163
ISIN
US4923271013
Website
KROS Metrics
BasicAdvanced
$550M
124.36
$0.11
1.29
-
Price and volume
Market cap
$550M
Beta
1.29
52-week high
$67.89
52-week low
$9.12
Average daily volume
697K
Financial strength
Current ratio
19.287
Quick ratio
18.79
Long term debt to equity
2.238
Total debt to equity
2.526
Profitability
EBITDA (TTM)
-9.014
Gross margin (TTM)
95.13%
Net profit margin (TTM)
1.96%
Operating margin (TTM)
-4.80%
Effective tax rate (TTM)
71.06%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
-1.01%
Return on equity (TTM)
0.71%
Valuation
Price to earnings (TTM)
124.358
Price to revenue (TTM)
2.439
Price to book
0.75
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
12.093
Free cash flow yield (TTM)
8.27%
Free cash flow per share (TTM)
112.04%
Growth
Revenue change (TTM)
91,657.69%
Earnings per share change (TTM)
-102.13%
3-year revenue growth (CAGR)
120.24%
3-year earnings per share growth (CAGR)
-66.31%
What the Analysts think about KROS
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
Bulls say / Bears say
Keros Therapeutics reported a net income of $148.5 million in Q1 2025, a significant turnaround from a net loss of $43.1 million in the same period the previous year, primarily due to revenue from a license agreement with Takeda Pharmaceuticals. (finviz.com)
The company announced initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives, positioning it to advance to a Phase 2 clinical trial in Q1 2026. (finviz.com)
Jefferies initiated coverage of Keros Therapeutics with a 'buy' rating and a $107 price target, indicating strong confidence in the company's growth potential. (investing.com)
In December 2024, Keros halted dosing in two arms of a mid-stage trial for its lung disorder drug, cibotercept, due to safety concerns, leading to a significant stock price decline. (bnnbloomberg.ca)
Following the trial halt, BTIG Research downgraded Keros Therapeutics from a 'buy' to a 'neutral' rating, reflecting reduced confidence in the company's near-term prospects. (mayfieldrecorder.com)
The adoption of a 'poison pill' plan in April 2025 to prevent hostile takeovers may signal internal concerns about the company's valuation and strategic direction. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
KROS Financial Performance
Revenues and expenses
KROS Earnings Performance
Company profitability
KROS News
AllArticlesVideos
Keros Announces Return of $375 Million in Excess Capital to Stockholders
GlobeNewsWire·2 weeks ago
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·2 weeks ago
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $550M as of June 20, 2025.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 124.36 as of June 20, 2025.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.